ATE499104T1 - Progesterone dosierungsanweisung in der behandlung einer traumatischen verletzung des gehirns - Google Patents

Progesterone dosierungsanweisung in der behandlung einer traumatischen verletzung des gehirns

Info

Publication number
ATE499104T1
ATE499104T1 AT08167618T AT08167618T ATE499104T1 AT E499104 T1 ATE499104 T1 AT E499104T1 AT 08167618 T AT08167618 T AT 08167618T AT 08167618 T AT08167618 T AT 08167618T AT E499104 T1 ATE499104 T1 AT E499104T1
Authority
AT
Austria
Prior art keywords
brain
treatment
traumatic injury
nervous system
central nervous
Prior art date
Application number
AT08167618T
Other languages
English (en)
Inventor
Stuart W Hoffman
Arthur L Kellerman
Donald G Stein
David W Wright
Douglas W Lowery-North
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory filed Critical Univ Emory
Application granted granted Critical
Publication of ATE499104T1 publication Critical patent/ATE499104T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
AT08167618T 2005-03-24 2006-03-24 Progesterone dosierungsanweisung in der behandlung einer traumatischen verletzung des gehirns ATE499104T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66472805P 2005-03-24 2005-03-24
US72966305P 2005-10-24 2005-10-24

Publications (1)

Publication Number Publication Date
ATE499104T1 true ATE499104T1 (de) 2011-03-15

Family

ID=36987966

Family Applications (2)

Application Number Title Priority Date Filing Date
AT06739662T ATE520404T1 (de) 2005-03-24 2006-03-24 Verfahren zur behandlung einer verletzung des zentralen nervensystems durch ausschleichende verabreichung von progesteron
AT08167618T ATE499104T1 (de) 2005-03-24 2006-03-24 Progesterone dosierungsanweisung in der behandlung einer traumatischen verletzung des gehirns

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT06739662T ATE520404T1 (de) 2005-03-24 2006-03-24 Verfahren zur behandlung einer verletzung des zentralen nervensystems durch ausschleichende verabreichung von progesteron

Country Status (16)

Country Link
US (4) US20090221544A1 (de)
EP (5) EP1868614B1 (de)
JP (5) JP5394059B2 (de)
AT (2) ATE520404T1 (de)
AU (2) AU2006226774B2 (de)
CA (2) CA2601715C (de)
CY (2) CY1111478T1 (de)
DE (1) DE602006020353D1 (de)
DK (2) DK1868614T3 (de)
ES (2) ES2392454T3 (de)
HK (3) HK1112579A1 (de)
HR (2) HRP20110198T1 (de)
PL (2) PL2030622T3 (de)
PT (2) PT2030622E (de)
RS (1) RS52471B (de)
WO (2) WO2006102644A2 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7473687B2 (en) 2005-03-24 2009-01-06 Emory University Methods for the treatment of a traumatic central nervous system injury
EP1868614B1 (de) * 2005-03-24 2012-08-08 Emory University Dosierschema zur behandlung einer traumatischen gehirnverletzung mit progesteron
EP2052724A1 (de) * 2007-10-26 2009-04-29 sanofi-aventis Verwendung von Norgestimat als selektivem Hemmer der Ionenkanäle TRPC3, TRPC6 sowie TRPC6 und TRPC7
AU2009219230A1 (en) 2008-02-26 2009-09-03 Emory University Steroid analogues for neuroprotection
EP2331571B1 (de) 2008-09-18 2015-08-26 Northwestern University Nmda-rezeptormodulatoren und ihre verwendung
US20110306579A1 (en) * 2009-01-30 2011-12-15 Emory University Methods of neuroprotection using neuroprotective steroids and a vitamin d
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
US10993879B2 (en) * 2010-02-08 2021-05-04 Shenzhen Evergreen Therapeutics Co., Ltd. Pulmonary delivery of progestogen
US20110262502A1 (en) * 2010-02-08 2011-10-27 Prairie Pharmaceuticals LLC Pulmonary delivery of 17-hydroxyprogesterone caproate (17-hpc)
US10987361B2 (en) 2010-02-08 2021-04-27 Shenzhen Evergreen Therapeutics Co., Ltd. Treating auto-immune and auto-inflammatory diseases
ES2773079T3 (es) 2010-02-08 2020-07-09 Shenzhen Evergreen Therapeutics Co Ltd Métodos para el uso de progestágeno como sensibilizador de glucocorticoides
TW201138782A (en) 2010-04-26 2011-11-16 Besins Healthcare Lu Sarl Low-oil pharmaceutical emulsion compositions comprising progestogen
SG10202010665YA (en) * 2011-04-27 2020-11-27 Univ Northwestern Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders
US10478505B2 (en) 2011-09-23 2019-11-19 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
LT2806877T (lt) * 2012-01-23 2019-12-10 Sage Therapeutics Inc Neuroaktyvios steroidų kompozicijos, apimančios alopregnanolono ir sulfobutilo eterio beta-ciklodekstrino kompleksą
US20130210785A1 (en) 2012-02-15 2013-08-15 Emory University Progesterone analogs and uses related thereto
CN110251463A (zh) 2012-02-29 2019-09-20 贝朗医疗有限公司 含激素的乳液
RU2498826C1 (ru) * 2012-05-14 2013-11-20 Федеральное государственное бюджетное учреждение науки Комплексный научно-исследовательский институт им. Х.И. Ибрагимова Российской академии наук Способ лечения больных с черепно-мозговой травмой
IL275725B (en) * 2012-08-21 2022-08-01 Sage Therapeutics Inc Treatment methods for epilepsy and status epilepticus
EP2925327B1 (de) 2012-11-30 2024-01-10 The Regents of The University of California Allopregnanolon zur behandlung, verminderung oder milderung von symptomen der wochenbettdepression
AU2014212501A1 (en) 2013-01-29 2015-07-30 Aptinyx, Inc. Spiro-lactam NMDA receptor modulators and uses thereof
EA201591404A1 (ru) 2013-01-29 2016-01-29 Аптиникс Инк. Спиролактамные модуляторы рецептора nmda и их применение
AU2014212485C1 (en) 2013-01-29 2018-10-25 Aptinyx, Inc. Spiro-lactam NMDA receptor modulators and uses thereof
CA2898863A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
HUE043843T2 (hu) 2013-01-29 2019-09-30 Aptinyx Inc Spiro-laktám NMDA receptor modulátorok és azok alkalmazása
EP3978507A1 (de) 2013-08-12 2022-04-06 Emory University Progesteronphosphatanaloga und damit einhergehende verwendungen
US10231979B2 (en) * 2015-08-07 2019-03-19 Indiana University Research And Technology Corporation Modulation of inflammation using progesterone metabolites
WO2017156103A1 (en) 2016-03-08 2017-09-14 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
CA3024606C (en) 2016-05-19 2019-09-03 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
BR112019001926A2 (pt) 2016-08-01 2019-08-06 Aptinyx Inc moduladores do receptor nmda espiro-lactama e bis-espiro-lactama e usos destes
CA3031534C (en) 2016-08-01 2023-10-17 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
JP7032378B2 (ja) 2016-08-01 2022-03-08 アプティニックス インコーポレイテッド スピロ－ラクタムｎｍｄａ受容体修飾因子及びその使用
BR112019001768A2 (pt) 2016-08-01 2019-06-11 Aptinyx Inc moduladores do receptor de spiro-lactamas nmda e usos dos mesmos
EP3490990B1 (de) 2016-08-01 2023-12-06 Tenacia Biotechnology (Hong Kong) Co., Limited Spirolactam-nmda-modulatoren und verfahren zu deren verwendung
WO2019152687A1 (en) 2018-01-31 2019-08-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
US11216742B2 (en) 2019-03-04 2022-01-04 Iocurrents, Inc. Data compression and communication using machine learning
WO2023102149A1 (en) * 2021-12-02 2023-06-08 MarvelBiome, Inc. Methods and uses of microbiome compositions, components, or metabolites for treating vagus nerve associated diseases, disorders, and conditions
WO2024059056A1 (en) * 2022-09-12 2024-03-21 Emory University Methods of managing traumatic brain injury

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5217085A (en) 1975-07-30 1977-02-08 Ono Pharmaceut Co Ltd Method of quantitative determination of free fatty acids in serum usin g fatty acid activating enzymes
US4404366A (en) * 1980-05-06 1983-09-13 Miles Laboratories, Inc. Beta-galactosyl-umbelliferone-labeled hapten conjugates
US4369250A (en) 1981-07-31 1983-01-18 Sherwood Medical Industries Inc. Fatty acid determination
US5120723A (en) * 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
US5232917A (en) * 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
AU609927B2 (en) 1987-08-25 1991-05-09 Kelvin W. Gee Compositions and methods for alleviating stress, anxiety and seizure activity
USRE35517E (en) * 1987-08-25 1997-05-20 University Of Southern California Method, compositions, and compounds for modulating brain excitability
US5512429A (en) 1989-09-19 1996-04-30 British Technology Group Limited Assay for enzyme activity
GB9105707D0 (en) 1991-03-18 1991-05-01 Wilton David C Assay
US5114388A (en) * 1991-07-26 1992-05-19 True Fitness Technology, Inc. Stair simulator exerciser with adjustable incline
US5212167A (en) * 1991-09-12 1993-05-18 Trustees Of Boston University Modulation of receptor-mediated ion transport
US5206415A (en) * 1991-12-20 1993-04-27 Washington University Tricyclic steroid analogs
US5776923A (en) * 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
ATE275957T1 (de) * 1993-01-19 2004-10-15 Endorech Inc Therapeutische verwendungen und verabreichungsysteme von dehydroepiandrosteron
DE4311870C2 (de) 1993-04-10 1998-07-30 Altramed Holdings Ltd Verwendung eines Anti-Östrigens zur Therapie und Prophylaxe von Demenz-Erkrankungen
US5763431A (en) * 1993-08-20 1998-06-09 Jackson; Meyer B. Method for regulating neuropeptide hormone secretion
AU7569194A (en) * 1993-08-20 1995-03-21 Meyer B. Jackson Method for regulating neuropeptide hormone secretion
US5939545A (en) * 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
US5633011A (en) * 1994-08-04 1997-05-27 Alza Corporation Progesterone replacement therapy
US5767117A (en) * 1994-11-18 1998-06-16 The General Hospital Corporation Method for treating vascular headaches
FR2727117A1 (fr) * 1994-11-18 1996-05-24 Geffard Michel Utilisation de conjugues de la polylysine pour la preparation de medicaments utiles dans le traitement des maladies neurodegeneratives et des affections degeneratives a caractere autoimmun
US5837544A (en) * 1995-02-02 1998-11-17 Cell Genesys, Inc. Method of inducing a cell to proliferate using a chimeric receptor comprising janus kinase
ES2235187T3 (es) * 1995-06-06 2005-07-01 Euro-Celtique S.A. Esteroides neuroactivos de las series del androstano y el pregnano.
EP0778768B1 (de) * 1995-06-09 2004-05-26 Euroceltique S.A. Formulierungen und verfahren für eine verlängerte lokalanästhesie
US5888996A (en) * 1995-07-26 1999-03-30 Trustees Of Boston University Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity
JP2000513336A (ja) 1996-05-22 2000-10-10 ディバーシファイド ファーマシューティカルズ，インコーポレーテッド 薬物の経皮送達のための組成物、方法及びデバイス
US5763492A (en) * 1996-10-01 1998-06-09 Duguesne University Of The Holy Ghost Methods for effecting memory enhancement mediated by non-steroidal sulfatase inhibitors
EP0981349B1 (de) 1997-05-02 2002-11-06 Wyeth 5-alpha-pregnan-3-beta-ol-20-one 3-sulfate für di behandlung von tumoren und zns krankheiten
US6245757B1 (en) * 1997-10-03 2001-06-12 Research Corporation Technologies, Inc. Use of progestins to treat ischemic event
US6174547B1 (en) * 1999-07-14 2001-01-16 Alza Corporation Dosage form comprising liquid formulation
US6268223B1 (en) 1999-08-27 2001-07-31 Viatech Imagin, Llc Assay for detecting damage to the central nervous system
US20020072509A1 (en) * 2000-10-11 2002-06-13 Stein Donald Gerald Methods for the treatment of a traumatic central nervous system injury
EP1868614B1 (de) * 2005-03-24 2012-08-08 Emory University Dosierschema zur behandlung einer traumatischen gehirnverletzung mit progesteron
US7473687B2 (en) * 2005-03-24 2009-01-06 Emory University Methods for the treatment of a traumatic central nervous system injury

Also Published As

Publication number Publication date
DK1868614T3 (da) 2012-11-12
EP2431042B1 (de) 2013-06-26
JP5295755B2 (ja) 2013-09-18
CY1113253T1 (el) 2016-04-13
EP2030622A1 (de) 2009-03-04
CA2602950A1 (en) 2006-09-28
HK1128242A1 (en) 2009-10-23
US20120289491A1 (en) 2012-11-15
HRP20120688T1 (hr) 2012-09-30
HK1112581A1 (en) 2008-09-12
EP1871382B1 (de) 2011-08-17
PT2030622E (pt) 2011-06-02
CY1111478T1 (el) 2015-08-05
JP2013234191A (ja) 2013-11-21
HK1112579A1 (en) 2008-09-12
EP1868614A2 (de) 2007-12-26
WO2006102644A2 (en) 2006-09-28
JP5496407B2 (ja) 2014-05-21
RS52471B (en) 2013-02-28
PL1868614T3 (pl) 2013-01-31
EP2494976A1 (de) 2012-09-05
US20090325920A1 (en) 2009-12-31
DE602006020353D1 (de) 2011-04-07
AU2006226811B2 (en) 2010-11-25
CA2601715C (en) 2012-10-16
ES2428313T3 (es) 2013-11-07
EP2030622B1 (de) 2011-02-23
EP1868614B1 (de) 2012-08-08
AU2006226774B2 (en) 2010-12-02
WO2006102596A2 (en) 2006-09-28
JP2008534512A (ja) 2008-08-28
DK2030622T3 (da) 2011-05-02
JP2011225629A (ja) 2011-11-10
ES2392454T3 (es) 2012-12-10
AU2006226774A1 (en) 2006-09-28
AU2006226811A1 (en) 2006-09-28
WO2006102596A3 (en) 2007-01-18
CA2602950C (en) 2012-10-30
ATE520404T1 (de) 2011-09-15
JP5394059B2 (ja) 2014-01-22
JP2008534515A (ja) 2008-08-28
EP2431042A1 (de) 2012-03-21
US20090221544A1 (en) 2009-09-03
JP2014055183A (ja) 2014-03-27
US20120245133A1 (en) 2012-09-27
WO2006102644A3 (en) 2007-03-01
PL2030622T3 (pl) 2011-07-29
WO2006102644A9 (en) 2006-11-23
PT1868614E (pt) 2012-11-23
US8614203B2 (en) 2013-12-24
CA2601715A1 (en) 2006-09-28
HRP20110198T1 (hr) 2011-04-30
EP1871382A2 (de) 2008-01-02

Similar Documents

Publication Publication Date Title
ATE499104T1 (de) Progesterone dosierungsanweisung in der behandlung einer traumatischen verletzung des gehirns
PH12019502254A1 (en) Methods and systems for modulating stimuli to the brain with biosensors
WO2008039898A3 (en) Methods for the treatment of a traumatic central nervous system injury
EA201000603A1 (ru) ПРИМЕНЕНИЕ АНТИТЕЛ К TrkB ДЛЯ ЛЕЧЕНИЯ РЕСПИРАТОРНЫХ НАРУШЕНИЙ
BR112013007681A2 (pt) uso terapêutico de um agonista trl e terapia de combinação
WO2012106444A3 (en) Methods, devices and systems for treating insomnia by inducing frontal cerebral hypothermia
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
WO2017190044A8 (en) Methods for detecting and treating pain using brain activity
WO2008033440A3 (en) Treatment of hyperproliferative diseases with anthraquinones
RU2013122987A (ru) Способ лечения комбинированного радиационно-термического поражения
ATE485819T1 (de) Benzamidin derivative zur behandlung und vorbeugung von mucositis
WO2017011356A3 (en) Mcj inhibitors for use in treating drug-induced diseases and conditions
EP2566856A4 (de) Verbindungen und verfahren zur behandlung von hirnerkrankungen
WO2009111681A3 (en) Gallium compounds and methods of use to treat inflammatory bowel disease
WO2014201084A3 (en) Piroxicam transdermal composition to treat plantar fasciitis
MX2015013137A (es) Compuestos novedosos de modulación del control de la respiración, y sus métodos de uso.
MX2019001337A (es) Métodos para tratar y prevenir efectos secundarios por tratamiento de cáncer.
WO2011071981A3 (en) Anti-cytomegalovirus activity of artemisinin-derived dimers
ATE510530T1 (de) Verfahren zur verhinderung und/oder behandlung von altersflecken
WO2008128155A3 (en) SIRTUIN BASED METHODS AND COMPOSITIONS FOR TREATING β- CATENIN-RELATED CONDITIONS
MXPA05012696A (es) Formulaciones de agentes antiinflamatorios no esteroides para tratar angiogenesis ocular patologica.
WO2006096458A3 (en) Treatment of hyperproliferative diseases with anthraquinones
WO2015051279A3 (en) Cxcr4 up- and down-regulation for treatment of diseases or disorders
김유찬 DonSymposium 2-2-2 (SYP 2-2-2): Intensified photodynamic therapy
Osiecka Diclofenac/tazarotene

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2030622

Country of ref document: EP